.jpg)
There’s nothing more discouraging than taking depression medication consistently without seeing improvement. If you’re experiencing treatment-resistant depression, frustration and hopelessness aren’t the end of the road. “The main thing I want people to know is that there are some really good treatment options. You don’t have to just stay depressed,” says Steve Harvey, MD, regional medical director at Radial and a board-certified psychiatrist. “There's a new generation of treatments out there, including Spravato.”
Spravato is an FDA-approved medication that provides hope for many patients who otherwise haven't had success treating depression. Continue reading to learn more about the two conditions for which Spravato is FDA-approved and what emerging research says about other Spravato uses.


.png)
Spravato is used to treat major depressive disorder (MDD) with suicidal ideation and treatment-resistant depression. But before we get into specifics about Spravato treatment for those conditions, let's review what Spravato is.
Spravato is the brand name for esketamine nasal spray that is FDA-approved and administered in a REMS-certified clinic. Spravato targets glutamate — a brain chemical that plays a role in mood regulation — instead of serotonin, norepinephrine, or dopamine, which are targeted by most traditional antidepressants.
The first FDA-approved use is for treatment-resistant depression (TRD), which is admittedly a bit misleading. On the surface, the condition seems to be describing depression that won't respond to any treatments, but this isn’t exactly the case. Instead, Dr. Harvey says that TRD refers to instances where the depression has not responded to two or more oral antidepressants such as SSRIs and SNRIs.
Where it gets complicated is what counts as “trying a medication." Insurance companies often have different policies on who is eligible for Spravato treatment, so it’s worth reading your policy and discussing with a qualified prescriber who understands how the definition of treatment-resistant depression can vary.
When used for TRD, Spravato can be a monotherapy — or the only antidepressant treatment someone receives. Alternatively, someone can take it in tandem with an oral antidepressant.
MDD with suicidal ideation is the second FDA-approved use of Spravato. This is when someone experiences symptoms of MDD along with thoughts about ending one’s life and/or suicidal actions.
However, there’s an important nuance with this indication. The FDA label states Spravato on its own hasn’t been shown to prevent suicide. To reduce suicidal thoughts, the FDA recommends using it with an oral antidepressant and hospitalization may be necessary if someone cannot remain safe.
You also don’t have to wait until an appointment with a psychiatrist to get help. Immediate crisis support is available for free via the 988 Lifeline.

Spravato is not FDA-approved for any other uses besides treatment-resistant depression and MDD with acute suicidal ideation or behavior. Spravato is not FDA-approved for the following uses:
Spravato is also not an at-home option. A patient self-administers Spravato in a certified clinic under the supervision of a medical professional. Afterwards, they must remain at the clinic for a 2-hour monitoring period and then arrange a ride home. If someone doesn’t have a way to get to and from the clinic without driving themselves, Dr. Harvey often explores other treatment options, like transcranial magnetic stimulation (TMS).
.jpg)
Sometimes Spravato is prescribed off-label, which is when a medication is prescribed for a different purpose than the ones on the FDA label. Off-label uses are permitted under US healthcare regulations, per the FDA, though a medical professional must assess if the off-label use is medically necessary.
Additionally, many insurance plans won’t cover off-label uses, meaning patients might have to pay the entire cost out of pocket. Without insurance coverage, the Spravato cost can be quite high, so off-label use might not work for everyone’s budget.
When prescribed off-label, Spravato is still administered the same way: in a certified clinic with on-site monitoring. The patient must remain at the clinic under medical supervision for no less than two hours. They also need to arrange for transportation after treatment, since you cannot drive after receiving Spravato until you've had a full night of sleep.
A clinician might consider off-label use of Spravato for bipolar depression, anxious depression, and other conditions that have some clinical evidence to support Spravato’s effectiveness. Sometimes, it may also be prescribed for people who have MDD but have not yet “failed” two or three antidepressants. If, for example, someone had a bad adverse reaction to their first antidepressant, a psychiatrist may recommend Spravato off-label as opposed to another traditional antidepressant.
There’s growing research to support Spravato for PTSD, OCD, and other conditions. However, this research is in its early stages, and none of these emerging uses of Spravato are FDA-approved at this time.
It’s important to note that the majority of these studies share one thing in common: People had the stated condition and some form of depression. This doesn’t mean Spravato can’t help with these conditions, just that we need to be clear about the full context of the research.
While Spravato is a promising treatment for patients with multiple conditions in addition to depression, there are some patients for which Spravato is contraindicated or not recommended. Because Spravato can make psychosis worse and carries the potential for addiction, people who have experienced psychosis or struggled with substance use in the past are not good candidates for Spravato, and active substance use is contraindicated with Spravato.
Other conditions that may indicate you're not a candidate for Spravato include pregnancy, elevated blood pressure, aneurysm, and a history of brain bleeds. What's more, co-prescribing opioids, benzodiazepines, and some sleep medications can increase the risk of adverse events when taking Spravato.
The best way to determine if Spravato is right for you is to have a conversation with a qualified prescriber at a certified clinic. Psychiatrists and other mental health providers (like psychiatric-mental health nurse practitioners, or PMHNPs) can prescribe Spravato when they work at a REMS-certified clinic, such as Radial. REMS is a federal program that ensures medications that require specific monitoring are administered in a safe way, including but not limited to Spravato, isotretinoin, and clozapine, to name a few.
During a consultation, a qualified prescriber can determine if you meet standard eligibility requirements, as well as if this medication or another treatment option suits your overall health, lifestyle, and insurance requirements.
Dr. Harvey reflects that when patients come in with treatment-resistant depression, there are two alternative treatments for depression that he is most likely to explore: transcranial magnetic stimulation (TMS) and Spravato.
When exploring these options, he considers if the patient has any contraindications (medical reasons they can’t do one or the other) as well as their comfort with each potential treatment.
You can learn more about how the two treatments compare in our TMS vs. Spravato guide.
Radial provides advanced mental health treatment, covered by the insurance you already use.
The main Spravato uses are for treatment-resistant depression and MDD with acute suicidal ideation. For people with these conditions, Spravato may provide rapid, much-needed relief. It may also help with other mental health conditions and chronic pain, though these are off-label uses and are not FDA-approved. To learn more about whether Spravato is right for you, talk to a qualified psychiatric provider, such as the team at Radial.
Disclaimer: The doctor quoted in this article, Steve Harvey, MD, is a paid speaker for Johnson & Johnson, the manufacturer of Spravato.
Spravato is a prescription medication that’s classified as a controlled substance. This means that if the drug is misused, there could be adverse effects, including addiction and withdrawal. To combat these risks, Spravato is only administered in certified clinics following FDA-approved treatment protocols once medical necessity is established by a licensed clinician.
Spravato cannot be taken at home. While you self-administer this nasal spray, you must do so in a certified clinic and then stay for the mandatory 2-hour minimum medically supervised monitoring period.
While similar, Spravato and ketamine are not the same thing. Ketamine is a mixture of two mirror-image molecules (R-ketamine and S-ketamine) whereas Spravato contains only S-ketamine. Spravato is FDA-approved for MDD with suicidal ideation and treatment-resistant depression, meaning it’s more likely to be covered by insurance for these uses. Ketamine is FDA-approved only as a general anesthetic.
At Radial, we believe better health starts with trusted information. Our mission is to empower readers with accurate, accessible, and compassionate content rooted in evidence-based research and reviewed by qualified medical professionals. We’re committed to ensuring the quality and trustworthiness of our content and editorial process–and providing information that is up-to-date, accurate, and relies on evidence-based research and peer-reviewed journals. Learn more about our editorial process.
Get started with finding the right treatment for you or someone you care about
Get started